Doxifluridine
Specifications
3094-09-5CAS Number
221-440-1EC Number
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoropyrimidine-2,4-dioneIUPAC Name
C9H11FN2O5Chemical Formula
246.19 g/molMolecular Weight
doxifluridine; 5'-Deoxy-5-fluorouridine; 5-fluoro-5'-deoxyuridine; Furtulon; 3094-09-5; Uridine, 5'-deoxy-5-fluoro-; Flutron; 5'-Dfur; Doxifluridina; Doxifluridinum; Fulturon; DTXSID2022967; Ro 219738; Uridine-5'-deoxy-5-fluoro-; Ro 21-9738; 5-DFUR; V1JK16Y2JP; 1-(beta-D-5-Desoxyribofuranoxyl)-5-fluoruracil; NSC-758890; RO-219738; DTXCID602967; CHEBI:31521; doxyfluridine; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl]-5-fluoro-pyrimidine-2,4-dione; 5'-fluoro-5'-deoxyuridine; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl)-5-fluoro-pyrimidine-2,4-dione; RefChem:590413; 221-440-1; 5'-deoxy-5'-fluorouridine; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1H,3H)-dione; MFCD00866530; 5'-dFUrd; CHEMBL1130; NCGC00093926-03; 5'dFUrd; 5'-Doxifluridine; Furtulon (TN); SMR000326811; CAS-3094-09-5; SR-01000075886; Doxifluridine [INN:JAN]; Doxifluridinum [INN-Latin]; Doxifluridina [INN-Spanish]; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoropyrimidine-2,4-dione; EINECS 221-440-1; Ro-21-9738; Doxifluridine (Standard); DOXIFLURIDINE [MI]; 5-Deoxy-5'-fluorouridine; 5-Fluoro-5`-deoxyuridine; UNII-V1JK16Y2JP; DOXIFLURIDINE [INN]; DOXIFLURIDINE [JAN]; SCHEMBL8094; Capecitabine impurity B CRS; 5'-Deoxy-5-fluorouridine;; Doxifluridine (JP18/INN); Lopac0_000537; MLS001332579; MLS001332580; MLS002172440; MLS002207077; DOXIFLURIDINE [MART.]; DOXIFLURIDINE [WHO-DD]; orb1225346; orb1308065; orb3141437; SCHEMBL27598202; HY-B0021R; HMS2090C22; HMS2231I05; HMS3261L15; HY-B0021; Tox21_111231; Tox21_500537; BDBM50132295; s2045; CAPECITABINE IMPURITY B (USP); AKOS015852921; AKOS015896821; Tox21_111231_1; 5-Fluoro-5'-deoxyuridine;doxifluridine; CCG-204627; CS-1270; DB12947; KS-5065; LP00537; NSC 758890; SDCCGSBI-0050520.P002; NCGC00093926-01; NCGC00093926-02; NCGC00093926-05; NCGC00093926-11; NCGC00093926-15; NCGC00261222-01; BP-58654; SRI-11552-08; SRI-11552_09; SY017052; 5''-Deoxy-5-Fluorouridine (5''-Dfur); DB-185809; D5692; EU-0100537; NS00046999; 5'-DEOXY-5-FLUOROURIDINE (5'-DFUR); D01309; F 8791; 5-Fluoro-5 inverted exclamation mark -deoxyuridine; F787567; Q1253473; SR-01000075886-1; SR-01000075886-5; BRD-K58262659-001-09-7; 1-(.BETA.-D-5-DESOXYRIBOFURANOXYL)-5-FLUORURACIL; Capecitabine impurity B, European Pharmacopoeia (EP) Reference Standard; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1H,3H)-dione; 1-((2R,5R)-3,4-Dihydroxy-5-methyl-tetrahydro-furan-2-yl)-5-fluoro-1H-pyrimidine-2,4-dione; 1-((4S,2R,3R,5R)-3,4-Dihydroxy-5-methyloxolan-2-yl)-5-fluoro-1,3-dihydropyrimidine-2,4-dione; 1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoropyrimidine-2,4(1H,3H)-dione (5'-Deoxy-5-fluorouridine)Synonyms
